[go: up one dir, main page]

DK3024497T3 - Fremgangsmåder og præparater til behandling af hjernesygdomme - Google Patents

Fremgangsmåder og præparater til behandling af hjernesygdomme Download PDF

Info

Publication number
DK3024497T3
DK3024497T3 DK14829704.7T DK14829704T DK3024497T3 DK 3024497 T3 DK3024497 T3 DK 3024497T3 DK 14829704 T DK14829704 T DK 14829704T DK 3024497 T3 DK3024497 T3 DK 3024497T3
Authority
DK
Denmark
Prior art keywords
preparations
treatment
methods
brain diseases
brain
Prior art date
Application number
DK14829704.7T
Other languages
English (en)
Inventor
Beverly L Davidson
Luis Tecedor
Yong Hong Chen
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of DK3024497T3 publication Critical patent/DK3024497T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK14829704.7T 2013-07-26 2014-07-20 Fremgangsmåder og præparater til behandling af hjernesygdomme DK3024497T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361859157P 2013-07-26 2013-07-26
PCT/US2014/047338 WO2015013148A2 (en) 2013-07-26 2014-07-20 Methods and compositions for treating brain diseases

Publications (1)

Publication Number Publication Date
DK3024497T3 true DK3024497T3 (da) 2021-04-12

Family

ID=52393945

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14829704.7T DK3024497T3 (da) 2013-07-26 2014-07-20 Fremgangsmåder og præparater til behandling af hjernesygdomme

Country Status (16)

Country Link
US (2) US10391184B2 (da)
EP (1) EP3024497B1 (da)
JP (2) JP6752142B2 (da)
KR (2) KR102423069B1 (da)
CN (1) CN105764532B (da)
AU (1) AU2014293460B2 (da)
BR (1) BR112016001592A2 (da)
CA (1) CA2918902C (da)
DK (1) DK3024497T3 (da)
ES (1) ES2859605T3 (da)
IL (1) IL243758B (da)
MX (1) MX373332B (da)
PT (1) PT3024497T (da)
RU (2) RU2018128780A (da)
WO (1) WO2015013148A2 (da)
ZA (1) ZA201601024B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1222093A1 (zh) * 2013-05-15 2017-06-23 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
RU2716422C2 (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2017014443A (es) * 2015-05-15 2018-08-01 Univ Minnesota Adeno-asociado para administracion terapeutica al sistema nervioso central.
AU2016341428B2 (en) * 2015-10-23 2021-12-02 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CA3252099A1 (en) 2016-05-18 2025-06-05 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
AU2017306558B2 (en) * 2016-08-03 2024-09-19 University Of South Florida Reelin compositions for treatment of neurological disorders
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
MX2019002518A (es) * 2016-09-02 2019-07-18 Spark Therapeutics Inc Metodos y vectores para el tratamiento de trastornos del snc.
JP2019537576A (ja) * 2016-11-04 2019-12-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. 筋萎縮性側索硬化症(als)治療組成物および方法
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
US11591614B2 (en) 2017-05-11 2023-02-28 The Trustees Of The University Of Pennsylvania Gene therapy for ceroid lipofuscinoses
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
CN119242711A (zh) 2017-10-16 2025-01-03 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3707264A1 (en) 2017-11-08 2020-09-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
BR112020023082A2 (pt) 2018-05-15 2021-02-09 Voyager Therapeutics, Inc. composições e métodos para o tratamento de doença de parkinson
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US12228571B2 (en) 2018-06-08 2025-02-18 Novartis Ag Cell-based assay for measuring drug product potency
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN113227126A (zh) * 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗
CA3127889A1 (en) * 2019-02-01 2020-08-06 Spark Therapeutics, Inc. Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2
MX2021010412A (es) * 2019-02-28 2022-01-24 Benitec Ip Holdings Inc Composiciones y metodos para tratar distrofia muscular oculofaringea (opmd).
JP2022526425A (ja) * 2019-04-12 2022-05-24 エンコーデッド セラピューティクス, インコーポレイテッド 治療剤の投与のための組成物および方法
KR102272858B1 (ko) 2019-05-22 2021-07-05 경희대학교 산학협력단 뇌 이상 단백질 치료를 위한 방사선 시스템 및 이의 사용 방법
RU2716013C2 (ru) * 2019-05-27 2020-03-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ изготовления средства для клеточно-опосредованной генной терапии и средство для клеточно-опосредованной генной терапии
US20230132582A1 (en) * 2020-03-11 2023-05-04 Shanghai Belief-Delivery Biomed Co., Ltd. Novel use of aspirin compound in increasing nucleic acid expression
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
WO2025084951A1 (en) * 2023-10-16 2025-04-24 Joint Stock Company "Axelgen" Recombinant genetic construct, adeno-associated virus for the treatment of metachromatic leukodystrophy
WO2025221877A1 (en) * 2024-04-17 2025-10-23 Five Prime Sciences Incorporated Tripeptidyl peptidase 1-related compositions and methods for the treatment and diagnosis of amyotrophic lateral sclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2171109A1 (en) * 1993-10-01 1995-04-13 Zvi Ram Gene therapy of the nervous system
AU6234099A (en) * 1998-10-16 2000-05-08 Introgene B.V. Gene therapy of alzheimer's disease by delivery of an encoded apoliprotein
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
CN101068575A (zh) * 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法
PL2489733T3 (pl) 2006-06-07 2019-08-30 Genzyme Corporation Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego
US9102949B2 (en) * 2010-04-23 2015-08-11 University Of Massachusetts CNS targeting AAV vectors and methods of use thereof
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
US9849195B2 (en) * 2011-03-31 2017-12-26 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
CA2870288A1 (en) * 2012-04-10 2013-10-17 John J. Rossi Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells

Also Published As

Publication number Publication date
BR112016001592A2 (pt) 2017-11-28
ZA201601024B (en) 2020-08-26
CA2918902A1 (en) 2015-01-29
EP3024497A2 (en) 2016-06-01
US10391184B2 (en) 2019-08-27
KR20160035596A (ko) 2016-03-31
MX373332B (es) 2020-05-21
MX2016001026A (es) 2016-08-03
RU2016106652A (ru) 2017-08-31
JP2016530246A (ja) 2016-09-29
JP6752142B2 (ja) 2020-09-09
AU2014293460B2 (en) 2019-10-24
RU2018128780A3 (da) 2022-04-13
IL243758B (en) 2019-11-28
CA2918902C (en) 2023-04-04
KR20220106852A (ko) 2022-07-29
EP3024497A4 (en) 2017-01-04
US20200009267A1 (en) 2020-01-09
HK1225305A1 (zh) 2017-09-08
JP6872579B2 (ja) 2021-05-19
RU2018128780A (ru) 2018-12-05
KR102423069B1 (ko) 2022-07-21
JP2019163281A (ja) 2019-09-26
PT3024497T (pt) 2021-08-23
CN105764532A (zh) 2016-07-13
AU2014293460A1 (en) 2016-02-18
RU2664471C2 (ru) 2018-08-17
WO2015013148A3 (en) 2015-11-05
WO2015013148A2 (en) 2015-01-29
US20160166709A1 (en) 2016-06-16
EP3024497B1 (en) 2021-01-13
ES2859605T3 (es) 2021-10-04
IL243758A0 (en) 2016-04-21
CN105764532B (zh) 2021-08-31

Similar Documents

Publication Publication Date Title
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
IL304429A (en) Methods and compositions for treatment of epileptic disorders
IL258955A (en) Compositions and methods for treatment of cancer
IL283432A (en) Compositions, methods and systems for the treatment of cutaneous disorders
DK3039146T3 (da) Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
LT3698847T (lt) Magnetinio stimuliavimo prietaisai terapinėms procedūroms
DK3142637T3 (da) Keratin treatment formulations and methods
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK2764881T3 (da) System til medicinsk behandling
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
IL251759B (en) Compositions and methods for treating insomnia
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
LT3007726T (lt) Tautopatijos gydymo būdai
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
IL233639B (en) Compositions and methods for the treatment of hepatic diseases and disorders
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK2968470T3 (da) Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme